Systems biology in drug discovery

Nature Biotechnology

Volumn 22, Issue 10, 2004, Pages 1253-1259

  Butcher, Eugene C ^a,b   Berg, Ellen L ^c   Kunkel, Eric J ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c BioSeek Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CELLS; COMPUTER SIMULATION; DECISION MAKING; DISEASE CONTROL; DRUG DOSAGE; GENES; METABOLITES; MOLECULAR BIOLOGY; PROTEINS; SYSTEMS ANALYSIS; TISSUE;

BIOLOGICAL SYSTEMS; DRUG DEVELOPMENT; DRUG DISCOVERY; HUMAN DISEASE;

DRUG PRODUCTS;

ASSAY; AUTOMATION; BIOLOGY; COMPUTER MODEL; COMPUTER SIMULATION; DECISION MAKING; DRUG DEVELOPMENT; METABOLITE; PRIORITY JOURNAL; REVIEW; SYSTEMS BIOLOGY;

ANIMALS; CELL PHYSIOLOGY; DRUG DESIGN; GENOMICS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR BIOLOGY; PROTEIN INTERACTION MAPPING; SYSTEMS BIOLOGY; TECHNOLOGY, PHARMACEUTICAL;

EID: 5044226336     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1017     Document Type: Review

References (39)

1. DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
2. Ideker, T., Galitski, T. & Hood, L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2, 343-372 (2001).
3. Ideker, T. & Lauffenburger, D. Building with a scaffold: emerging strategies for high- to low-level cellular modeling. Trends Biotechnol. 21, 255-262 (2003).
4. Hunter, P.J. & Borg, T.K. Integration from proteins to organs: the Physiome Project. Nat. Rev. Mol. Cell Biol. 4, 237-243 (2003).
5. Kulkarni, N.H. et al. Gene expression profiles classify different classes of bone therapies: PTH, Alendronate and SERMs, Poster 307, 31st European Symposium on Calicified Tissue, June 5, 2004, Nice, France; http://www.ectsoc. org/nice2004/abstracts.htm#onl
6. Weston, A.D. & Hood, L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J. Proteome. Res. 3, 179-196 (2004).
7. Clish, C.B. et al. Integrative biological analysis of the APOE*5-leiden transgenic mouse. Omics 8, 3-13 (2004).
8. Kantor, A.B. et al. Biomarker discovery by comprehensive phenotyping for autoimmune diseases. Clin. Immunol. 111, 186-195 (2004).
9. Davidson, E.H. et al. A genomic regulatory network for development. Science 295, 1669-1678 (2002).
10. Ideker, T. et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292, 929-934 (2001).
11. Covert, M.W., Knight, E.M., Reed, J.L., Herrgard, M.J. & Palsson, B.O. Integrating high-throughput and computational data elucidates bacterial networks. Nature 429, 92-96 (2004).
12. Hughes, T.R. et al. Functional discovery via a compendium of expression profiles. Cell 102, 109-126 (2000).
13. Crampin, E.J. et al. Computational physiology and the Physiome Project. Exp. Physiol 89, 1-26 (2004).
14. Noble, D. Modeling the heart-from genes to cells to the whole organ. Science 295, 1678-1682 (2002).
15. Bassingthwaighte, J.B. & Vinnakota, K.C. The computational integrated myocyte: a view into the virtual heart. Ann. NY Acad. Sci. 1015, 391-404 (2004).
16. Musante, C.J., Lewis, A.K. & Hall, K. Small- and large-scale biosimulation applied to drug discovery and development. Drug Discov. Today 7, S192-S196 (2002).
17. Stokes, C.L. et al. A computer model of chronic asthma with application to clinical studies: example of treatment of exercise-induced asthma. J. Allergy. Clin. Immunol. 107, 933 (2001).
18. Lewis, A.K. et al. The roles of cells and mediators in a computer model of chronic asthma. Inter. Arch. Allergy Immunol. 124, 282-286 (2001).
19. Leckie, M.J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2144-2148 (2000).
20. Bergman, R.N., Ider, Y.Z., Bowden, C.R. & Cobelli, C. Quantitative estimation of insulin sensitivity. Am. J. Physiol. 236, E667-E677 (1979).
21. Kansal, A.R. Modeling approaches to type 2 diabetes. Diabetes Technol. Ther. 6, 39-47 (2004).
22. Eungdamrong, N.J. & Iyengar, R. Modeling cell signaling networks. Biol. Cell 96, 355-362 (2004).
23. Bhalla, U.S. & Iyengar, R. Emergent properties of networks of biological signaling pathways. Science 283, 381-387 (1999).
24. Kelley, B.P. et al. PathBLAST: a tool for alignment of protein interaction networks. Nucleic Acids Res. 32, W83-W88 (2004).
25. Coleman, R.A., Bowen, W.P., Baines, I.A., Woodrooffe, A.J. & Brown, A.M. Use of human tissue in ADME and safety profiling of development candidates. Drug Discov. Today 6, 1116-1126 (2001).
26. Chanda, S.K. et al. Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc. Natl. Acad. Sci. USA 100, 12153-12158 (2003).
27. Haggarty, S.J., Koeller, K.M., Wong, J.C., Butcher, R.A. & Schreiber, S.L. Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem. Biol. 10, 383-396 (2003).
28. Borisy, A.A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA 100, 7977-7982 (2003).
29. Marton, M.J. et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4, 1293-1301 (1998).
30. Kunkel, E.J. et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 18, 1279-1281 (2004).
31. Kunkel, E.J. et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMAP analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2, 431-441 (2004).
32. Plavec, I. et al. Method for analyzing signaling networks in complex cellular systems. Proc. Natl. Acad. Sci. USA 101, 1223-1228 (2004).
33. Mach, F. Statins as novel immunomodulators: from cell to potential clinical benefit. Thromb. Haemost. 90, 607-610 (2003).
34. Christopher, R. et al. Data-driven computer simulation of human cancer cell. Ann. NY Acad. Sci. 1020, 132-153 (2004).
35. Wiley, H.S., Shvartsman, S.Y. & Lauffenburger, D.A. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol. 13, 43-50 (2003).
36. Schoeberl, B., Eichler-Jonsson, C., Gilles, E.D. & Muller, G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. 20, 370-375 (2002).
37. Eker, S. et al. Pathway logic: symbolic analysis of biological signaling. Pac. Symp. Biocomput. 7, 400-412 (2002).
38. Cho, K.H., Shin, S.Y., Lee, H.W. & Wolkenhauer, O. Investigations into the analysis and modeling of the TNF alpha-mediated NF-kappa B-signaling pathway. Genome Res. 13, 2413-2422 (2003).
39. Hoffmann, A., Levchenko, A., Scott, M.L. & Baltimore, D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298, 1241-1245 (2002).